News

TipRanks on MSN2d

MAIA Biotechnology highlights efficacy data from THIO-101 Phase 2 trial

MAIA Biotechnology (MAIA) highlights efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine sequenced with the immune ...
TipRanks on MSN2d

MAIA Biotechnology Reports Positive Phase 2 Trial Results

MAIA Biotechnology, Inc. ( ($MAIA) ) has provided an update. On September 11, 2025, MAIA Biotechnology announced positive ...
The Scientist6mon

Spatial Proteomics and Deep Visual Proteomics: A Revolution in Cell Biology

Spatial proteomics is the study of the spatial distribution of the proteins within cells and tissues. The subcellular localization of proteins is intrinsic to cellular function, making spatial ...
Nasdaq4mon

Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...
Morningstar18d

High-Precision Base Editing Clinical Treatment for Sickle Cell Disease — CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient

SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the ...
Nasdaq3mon

Beam Therapeutics Reports Positive Updated Data from BEACON Trial of BEAM-101 for Sickle Cell Disease

Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...